Overall Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Polish Experience

Abstract

Background The mortality caused by hepatocellular carcinoma is expected to rise in the upcoming decade. Sorafenib has become the preferred systemic treatment option in patients with unresectable HCC. This study aimed to present the median overall survival (OS) in a group of patients with advanced HCC, treated with sorafenib in Poland between 2011 and 2019. Material/Methods The analyzed group of patients was qualified for treatment with sorafenib, financed by the National Health Fund, based on the guidelines of the Polish Drug Program. Kaplan-Meier method was used to plot the OS curves, and the log-rank test was used for testing. Multivariate assessment of factors (sex and age) related to the time to death of the patient was done using Cox regression. Results Of the 2072 treated patients, 75% were men (1556) and 25% were women (516). The minimum age of patients in the trial group was 18 years and the maximum age was 90 years. Among the 1556 analyzed cases in males, 27.44% (427) did not end with death (by the date of completing the analysis). The percentage of one-year survival for this population was 58.16%, and the 2-, 3-, and 5-year survival rates were 34.45%, 21.81%, and 9.72%, respectively. The percentage of censored cases in the 516 females was 25.78% (133). The 1-2-, 3-, and 5-year survival for this population was 59.30%, 36.27%, 22.47%, and 11.34%, respectively. Statistical tests did not reveal a significant difference in the curve profiles by sex. There were no associations between OS and age. Conclusions Systemic treatment with sorafenib in accordance with the presented criteria allows for very good results, comparable to the results of selected groups of patients presented by other authors.

Linoleate-pazopanib conjugation as active pharmacological ingredient to abolish hepatocellular carcinoma growth

“…Due to the rich neo-vasculature pattern of HCC ( Anisha et al, 2021 ), many angiogenesis-targeting Multikinase Inhibitor (MKIs) have been developed ( Rahbari et al, 2016 ). Clinically, only a few inhibitors with limited efficacy, such as sorafenib ( Stra et al, 2021 ), lenvatinib ( Lee et al, 2022 ), regorafenib ( Iavarone et al, 2021 ) and cabozantinib ( Kelley et al, 2022 ), were employed. However, the overall survival rate of patients with advanced HCC is low and has not improved ( Toyoda et al, 2022 ).…”

Impact of Thrombocytopenia on Survival in Patients with Hepatocellular Carcinoma: Updated Meta-Analysis and Systematic Review

“…Currently, this involves a combination of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) [8]. Despite a better understanding of this disease and improvement in diagnostics and treatment, the prognosis for HCC is still poor with an overall 5-year survival rate estimated at approximately 20%, with some studies utilizing mainly TKI reporting rates as low as 9.72% for advanced HCC [2,9].…”